StreetInsider.com News Articles

Beam Therapeutics to present BEAM-302 trial data at ERS 2026

Thu, 23 Jul 2026 07:00:19 -0400

Beam Therapeutics Inc. (Nasdaq: BEAM) announced it will present updated clinical data from its Phase 1/2 trial of BEAM-302, a gene-editing therapy for alpha-1 antitrypsin deficiency (AATD), at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain, running September 5–9, 2026.

The presentation, titled "First-in-Human in vivo Gene Editing for Severe Alpha-1 Antitrypsin Deficiency (AATD): Initial Data from the Phase 1/2 Study of BEAM-302," is scheduled as a late-breaking oral presentation on September 8, 2026, from 9:30 to 10:45 a.m. CEST. John Hurst, M.D., Ph.D., of University College London, will serve as presenter.

BEAM-302 is a liver-targeting lipid-nanoparticle formulation designed to

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congres

Thu, 23 Jul 2026 07:00:00 -0400

Beam to Host Investor Webcast to Review BEAM-302 Clinical Data on Tuesday, September 8, 2026, at 7:00 a.m. ET

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026, taking place September 5–9, 2026, in Barcelona, Spain. BEAM-302 is Beam’s lead genetic disease program designed to be a best-in-class and first-in-class liver-targeting therapy for

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congres

Thu, 23 Jul 2026 07:00:00 -0400

Beam to Host Investor Webcast to Review BEAM-302 Clinical Data on Tuesday, September 8, 2026, at 7:00 a.m. ET

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congres

Thu, 23 Jul 2026 07:00:00 -0400

Beam to Host Investor Webcast to Review BEAM-302 Clinical Data on Tuesday, September 8, 2026, at 7:00 a.m. ET

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congres

Thu, 23 Jul 2026 07:00:00 -0400

Beam to Host Investor Webcast to Review BEAM-302 Clinical Data on Tuesday, September 8, 2026, at 7:00 a.m. ET

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

Wed, 08 Jul 2026 12:30:17 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

The analyst comments "PRME announced a positive binding arbitration resolution with BEAM over PM647 in AATD, confirming PM647 is in PRME’s field with no monetary damages. This removes a key investor overhang and clears the path for a Q3:26 filing, with initial data in 2027. We continue to view PRME as undervalued for the platform’s potential. Buy. PRME announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, with the tribunal declaring that PM647 falls within PRME’s “Field” under the companies’ 2019 Collaboration and

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

Wed, 08 Jul 2026 12:30:17 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

Wed, 08 Jul 2026 12:30:17 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

Wed, 08 Jul 2026 12:30:17 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff

Wed, 08 Jul 2026 11:32:20 -0400

BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

The analyst comments "The arbitration resolution (in favor of Prime Medicine, uncovered) in our view has limited impact to Beam as the ruling narrowly applies to PM647 rather than the overall prime editing estate. For context, Beam filed an AAA arbitration demand on April 16, 2025 alleging breach of the 2019 collaboration and license agreement, failure to transfer technical information, trade secret misappropriation and related business torts; Prime filed its own demand on April 18, 2025 seeking confirmation that its AATD

BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff

Wed, 08 Jul 2026 11:32:20 -0400

BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff

Wed, 08 Jul 2026 11:32:20 -0400

BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff

Wed, 08 Jul 2026 11:32:20 -0400

BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Tue, 07 Jul 2026 07:03:46 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

The analyst commented: "On June 30, we hosted a fireside chat with Beam's President Giuseppe Ciaramella, Ph.D., at H.C. Wainwright’s 4th Annual Cell Therapy Virtual Conference. Our fireside chat reinforced the two pillars of our investment thesis: risto-cel in sickle cell disease (SCD) and BEAM-302 in alpha-1 antitrypsin deficiency (AATD). On risto-cel, management is actively writing the biologics license application (BLA) and is on track to submit as early as the end of 2026, gated only on accumulating the final 15-month follow-up

Form 4 Beam Therapeutics Inc. For: Jun 30 Filed by: Simon Amy

Thu, 02 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260702/26727526.html

Form 4 Beam Therapeutics Inc. For: Jun 30 Filed by: Simon Amy

Thu, 02 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260702/26727526.html

Form 4 Beam Therapeutics Inc. For: Jun 29 Filed by: Evans John M.

Wed, 01 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260701/26720598.html

Form 4 Beam Therapeutics Inc. For: Jun 29 Filed by: Evans John M.

Wed, 01 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260701/26720598.html

Form 144 Beam Therapeutics Inc. Filed by: Evans John M.

Tue, 30 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260630/26713890.html

Form 144 Beam Therapeutics Inc. Filed by: Evans John M.

Tue, 30 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260630/26713890.html

Form 144 Beam Therapeutics Inc. Filed by: Evans John M.

Mon, 29 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260629/26706628.html

Form 144 Beam Therapeutics Inc. Filed by: Evans John M.

Mon, 29 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260629/26706628.html

Form 4 Beam Therapeutics Inc. For: Jun 25 Filed by: FMR LLC

Mon, 29 Jun 2026 14:17:00 -0400

si-local-file:///var/storage/secattach/20260629/26705500.html

Form 4 Beam Therapeutics Inc. For: Jun 25 Filed by: FMR LLC

Mon, 29 Jun 2026 14:17:00 -0400

si-local-file:///var/storage/secattach/20260629/26705500.html

Form 4 Beam Therapeutics Inc. For: Jun 17 Filed by: Ciaramella Giuseppe

Mon, 22 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260622/26672976.html